April 7, 2022 / 5:30-7:30pm PT

Join us at ASBrS 2022 for a symposium

Personalizing Care for Early Breast Cancer Patients: TAILORx, RxPONDER, and Beyond

Dr. Christy Russell (Vice President, US Medical Affairs at Exact Sciences) will lead a discussion with exploring how the Oncotype DX Breast Recurrence Score® test can help inform systemic therapy decisions for early node-negative and node-positive breast cancer patients. She will also explore ongoing studies on gene signatures that may help personalize radiotherapy decisions in early breast cancer.

Christy Russell, MD

Vice President, US Medical Affairs at Exact Sciences

Corey Speers, MD, PhD

Associate Professor of Radiation Oncology, University of Michigan Medical School

Jennifer Racz, MD

Director, Medical Affairs, Precision Oncology

I agree to be contacted by a representative of Exact Sciences about the Oncotype DX test and accept the Terms & Conditions. For more information about our privacy practices, please read our Privacy Policy.